Navigation Links
Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
Date:11/9/2007

Oral Presentation by Dr. Robert Figlin Highlights Phase 2 Data Showing 31% Partial Response Rate and a 62% Overall Clinical Benefit Rate to Perifosine Used as a Single Agent and Phase 1 Data Showing No Evidence of Increased

Toxicity When Combined with Sorafenib

NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced positive phase 1 & 2 data of perifosine (KRX-0401) in patients with advanced renal cell carcinoma (RCC). In an oral presentation entitled "PERIFOSINE: AN ORAL, AKT INHIBITOR WITH CLINICAL ACTIVITY IN ADVANCED RENAL CELL CARCINOMA," Dr. Robert Figlin, Medical Oncology Chair and Professor of Medicine, City of Hope National Medical Center in Duarte, CA provided an update on the clinical activity of single agent perifosine from a phase 2 trial (Protocol 207), and reported on the safety and efficacy of perifosine in combination with sorafenib from an ongoing phase I study (Protocol 124).

Phase 2 Single Agent in RCC - Protocol 207

Twenty-four patients with advanced renal cell carcinoma (RCC) were randomized to either the daily (50 mg or 100mg) or weekly (900mg or 1200mg) dose of perifosine. Patients with measurable disease who received at least 2 courses of perifosine and at least one tumor measurement after initiation of perifosine, were considered evaluable for response using RECIST criteria. Thirteen were evaluable for response. Four of these (31%) had a partial response and an additional 4 patients (31%) achieved long-term stable disease for a 62% overall clinical benefit rate. Five patients progressed. One of the responding patients had previously failed to respond to both sorafenib and sunitinib. The results are as follows:

50 1200

or or

100 mg 900 mg

Protocol 207
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
(Date:7/12/2014)... Response Management Systems is a crucial peak load management ... energy supply and demand. With the help of DRMS, ... increasing pressure on the grid) and replaced by Advanced ... and thermostats for load reduction. , DRMS is ... government mandates and benefits for energy efficiency and conservation ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Casinos ... years, despite rising competition from international and online casinos. ... 2.9% over the five years through 2014-15. Greater per ... demanding more gaming services. Rises in discretionary income levels ... more money on non-essential items such as casino gambling ...
(Date:7/12/2014)... Canada (PRWEB) July 12, 2014 Sean Francis, owner ... throwing out special challenges to his clients. He’s also known for ... He recently found a way to combine the two and is ... raised $2,000 for the Boys and Girls Club. , The funds ... which started on June 23rd. Francis sent out emails and asked ...
(Date:7/12/2014)... With prom shopping reaching its final days, VogueQueen.com, a ... showcase its new and trendy apparels. Recently, the company ... its online shop. Additionally, it is now providing huge ... According to the company’s sales manager, the promotion will ... , He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview with ... questions. Paddock tackles topics including main men's health ... longer than men, and testosterone replacement therapy, among others. ... featured on Doylestown Hospital’s website, Dr. Brad Paddock says, ... If you notice pain, bulging, or asymmetry in your ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... Hospital investigators have found that an electrically powered amplification ... to the acute hearing of humans and other mammals. ... loss can result from malfunction of this amplification machinery ... as aspirin. , Sound entering the cochlea is detected ...
... May 7 The following is a,statement by ... The guidelines for smoking cessation released today ... reminder to the nation,s 45 million,smokers that they ... quit smoking and protect their health than ever ...
... Presbyterian Hospital of,Plano has been named a recipient ... state,s highest honor for quality and organizational,performance., ... health care facility,in Collin County to receive this ... is the first hospital in parent company Texas ...
... thwarted rewiring needed for neural development, mouse study shows ... class of weight-loss drugs that suppresses appetite by blocking ... caution in children, U.S. scientists report. , In research ... suppresses the adaptive rewiring of the brain necessary for ...
... GAINESVILLE, Fla. Retinas in newborn mice appear perfectly fine ... microRNAs except for one thing the retinas do not ... the absence of microRNAs in the mammalian eye, an international ... the Italian National Research Council describes a gradual structural decline ...
... As part of its ongoing,commitment to providing the ... is excited to welcome Katherine Anne Binns as ... New York office. KN will,draw particularly on her ... growing list of clients., "Katherine possesses the ...
Cached Medicine News:Health News:St. Jude finds 'dancing' hair cells are key to humans' acute hearing 2Health News:St. Jude finds 'dancing' hair cells are key to humans' acute hearing 3Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 2Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 3Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 4Health News:Presbyterian Hospital of Plano Receives Prestigious Texas Award for Performance Excellence 2Health News:MicroRNAs appear essential for retinal health 2Health News:MicroRNAs appear essential for retinal health 3Health News:Senior Researcher With Extensive Healthcare Experience Joins Knowledge Networks 2
... throughput primary or backup instrument, this ... and reliability equal to or greater ... advanced technology of the AUTION JET ... reproducible and accurate results, limiting interference ...
... (E3) is one of the 3 major ... and estrone). In terms of estrogenic activity, ... [1]. Estriol is produced almost exclusively during ... in the normal human fetus. During pregnancy, ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
... Estrone (E1) is one of the ... include estradiol and estriol. Estrone is produced ... adrenal cortex or gonads [1,2]. In premenopausal ... is secreted by the ovary. In prepubertal ...
Medicine Products: